Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain
Aachen, Germany (ots) - - Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine. - The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. - Globally, more than 300 million patients ...